Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07019155 · ClinicalTrials.gov registry record
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
A clinical trial of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 510
- Enrollment target
- 1
- Study location
NCT07019155 is a study of Acute Myeloid Leukemia and Myelodysplastic Syndromes that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 510 participants, above the 114-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (347% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07019155, a study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 510 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Hereditary hematopoietic malignancy (HHM) syndromes are a group of inherited disorders that raises the risk of blood cancers. Many people with HHMs have changes in a gene (DDX41) that makes it more likely that they will develop myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or other cancers. This natural history study will explore the link between HHM syndromes and these diseases. Objective: To study the link between HHM and MDS/AML. Eligibility: People aged 1 month and older with HHM. Relatives with HHM are also needed. Design: Participants aged 3 years and older will have 1 initial clinic visit with the option to follow-up annually. They will undergo these procedures: They will have a physical exam with blood and urine tests. They may give samples of saliva, stool, nails, and skin. Their ability to do normal activities will be reviewed. Some may have a bone marrow biopsy: A tissue sample will be drawn from inside a bone. They may answer questions about their health and family medical history. Participants younger than 3 years, and those who cannot come to the clinic, will be contacted by phone or email. Their samples may be collected locally and sent to researchers. For participants who have changes in their DDX41 gene: Researchers will contact them or their primary care provider once a year for 10 years. Researchers will check on participants health and collect any new test results. Some may be asked to send new samples. Participants who do not have changes in their DDX41 gene may be contacted yearly, or less often, for 10 years. Some participants may be asked to return to the clinic if needed.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2025-07-24 |
| Est. Completion | 2035-06-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07019155
The ClinicalTrials.gov registry entry for NCT07019155 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 510 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 114-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (347% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 0 interventions.
NCT07019155 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT07019155 about?
NCT07019155 is a clinical study titled "Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants". Background: Hereditary hematopoietic malignancy (HHM) syndromes are a group of inherited disorders that raises the risk of blood cancers. Many people with HHMs have changes in a gene (DDX41) that makes it more likely that they will develop myelodysplastic syndrome (MDS), acute myeloid leukemia (AML...
What is the current status of trial NCT07019155?
This trial is currently recruiting. The enrollment target is 510 participants. The study started on 2025-07-24. Estimated completion is 2035-06-15.
What conditions does trial NCT07019155 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Germline Mutation.
Who is sponsoring clinical trial NCT07019155?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07019155 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)
RECRUITING
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.